Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

15.72USD
23 Sep 2016
Change (% chg)

$-0.15 (-0.95%)
Prev Close
$15.87
Open
$15.81
Day's High
$15.97
Day's Low
$15.70
Volume
251,546
Avg. Vol
325,208
52-wk High
$16.10
52-wk Low
$7.36

IRWD.OQ

Chart for IRWD.OQ

About

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company's products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $2,284.41
Shares Outstanding(Mil.): 145.32
Dividend: --
Yield (%): --

Financials

  IRWD.OQ Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -0.67 -- --
ROI: -16.06 -0.26 13.91
ROE: -87.00 -3.05 14.82

BRIEF-Ironwood Pharma Q2 adj shr loss $0.16

* Ironwood pharmaceuticals provides second quarter 2016 investor update

Aug 04 2016

BRIEF-Ironwood Pharmaceuticals Q1 gaap loss per share $0.09

* Ironwood pharmaceuticals provides first quarter 2016 investor update

May 09 2016

AstraZeneca sells U.S. gout drug rights to Ironwood for up to $265 million

British drugmaker AstraZeneca Plc said on Tuesday Ironwood Pharmaceuticals Inc would buy the U.S. marketing rights for its newly approved gout drug for up to $265 million.

Apr 26 2016

UPDATE 1-AstraZeneca sells U.S. gout drug rights to Ironwood for up to $265 mln

April 26 British drugmaker AstraZeneca Plc said on Tuesday Ironwood Pharmaceuticals Inc would buy the U.S. marketing rights for its newly approved gout drug for up to $265 million.

Apr 26 2016

BRIEF-Ironwood, AstraZeneca enter U.S. licensing agreement for lesinurad

* Ironwood Pharmaceuticals enters into U.S. licensing agreement with AstraZeneca for Lesinurad

Apr 26 2016

CORRECTED-AstraZeneca to sell US rights for gout drug for up to $265 mln

April 26 British drugmaker AstraZeneca Plc said Ironwood Pharmaceuticals Inc would buy the U.S. marketing rights for its newly-approved gout drug for up to $265 million.

Apr 26 2016

BRIEF-AstraZeneca, Ironwood agree U.S. licensing agreement

* Agreement includes U.S. rights to zurampic and lesinurad/allopurinol fixed-dose combination in gout

Apr 26 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.